EUVIMEDEUVIMED entdecken
Crossref

Recent Bendamustine Treatment Before Apheresis Has a Negative Impact on Outcomes in Patients With Large B-Cell Lymphoma Receiving Chimeric Antigen Receptor T-Cell Therapy

Gloria Iacoboni iD, Víctor Navarro iD, Ana África Martín-López, Kai Rejeski iD, Mi Kwon iD, Katarzyna Aleksandra Jalowiec iD, Paula Amat, Juan Luis Reguera-Ortega, Laura Gallur iD, Viktoria Blumenberg iD, Sara Gutiérrez-Herrero iD, Claire Roddie iD und 12 weitere

Journal of Clinical Oncology · 10.01.2024 · 42 (2) · 205-217

DOI: 10.1200/jco.23.01097 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Oncology, erschienen am 10.01.2024. Verfasst von Gloria Iacoboni und 23 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, University Hospital Vall d'Hebron, Barcelona, Spain. Hauptthemen laut MEDLINE: Receptors, Chimeric Antigen, Blood Component Removal, Lymphoma, Large B-Cell, Diffuse. Die Arbeit wurde bisher 130-mal zitiert (Crossref) und nennt 47 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE Approximately 30%-40% of patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL) infused with CD19-targeted chimeric antigen receptor (CAR) T cells achieve durable responses. Consensus guidelines suggest avoiding bendamustine before apheresis, but specific data in this setting are lacking. We report distinct outcomes after CAR T-cell therapy according to previous bendamustine exposure. METHODS The study included CAR T-cell recipients from seven European sites. Safety, efficacy, and CAR T-cell expansion kinetics were analyzed according to preapheresis bendamustine exposure. Additional studies on the impact of the washout period and bendamustine dose were performed. Inverse probability treatment weighting (IPTW) and propensity score matching (PSM) analyses were carried out for all efficacy comparisons between bendamustine-exposed and bendamustine-naïve patients. RESULTS The study included 439 patients with R/R LBCL infused with CD19-targeted commercial CAR T cells, of whom 80 had received bendamustine before apheresis. Exposed patients had significantly lower CD3 + cells and platelets at apheresis. These patients had a lower overall response rate (ORR, 53% v 72%; P < .01), a shorter progression-free survival (PFS, 3.1 v 6.2 months; P = .04), and overall survival (OS, 10.3 v 23.5 months; P = .01) in comparison with the bendamustine-naïve group. Following adjustment methods for baseline variables, these differences were mitigated. Focusing on the impact of bendamustine washout before apheresis, those with recent (

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptors, Chimeric AntigenBlood Component RemovalLymphoma, Large B-Cell, DiffuseHumansBendamustine HydrochlorideImmunotherapy, AdoptiveAntigens, CD19Cell- and Tissue-Based Therapy

Substanzen

Receptors, Chimeric AntigenBendamustine HydrochlorideAntigens, CD19

Autor:innen und Institutionen

  • Department of Hematology, University Hospital Vall d'Hebron, Barcelona, Spain.
  • Experimental Hematology, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.
  • Department of Medicine, Universitat Autònoma de Barcelona, Bellaterra, Spain.
  • Oncology Data Science (ODySey) Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.
  • Hematology Department, Hospital Clínico Universitario de Salamanca, IBSAL, CIBERONC, Salamanca, Spain.
  • Centro de Investigación del Cáncer-IBMCC, Salamanca, Spain.

ORCID-Profile: Gloria Iacoboni, Víctor Navarro, Kai Rejeski, Mi Kwon, Katarzyna Aleksandra Jalowiec, Laura Gallur, Viktoria Blumenberg, Sara Gutiérrez-Herrero, Claire Roddie, Ana Benzaquén, Rafael Hernani, Mariana Bastos, Maeve O'Reilly, Lourdes Martín-Martín, Marion Subklewe, Pere Barba

Zitieren

APA

Iacoboni, G., Navarro, V., Martín-López, A. Á., Rejeski, K., Kwon, M., Jalowiec, K. A., Amat, P., Reguera-Ortega, J. L., Gallur, L., Blumenberg, V., Gutiérrez-Herrero, S., Roddie, C., Benzaquén, A., Delgado-Serrano, J., Sánchez-Salinas, M. A., Bailén, R., Carpio, C., López-Corral, L., Hernani, R., …, & Barba, P. (2024). Recent Bendamustine Treatment Before Apheresis Has a Negative Impact on Outcomes in Patients With Large B-Cell Lymphoma Receiving Chimeric Antigen Receptor T-Cell Therapy. Journal of Clinical Oncology, 42(2), 205-217. https://doi.org/10.1200/jco.23.01097

Vancouver

Iacoboni G, Navarro V, Martín-López AÁ, Rejeski K, Kwon M, Jalowiec KA, et al. Recent Bendamustine Treatment Before Apheresis Has a Negative Impact on Outcomes in Patients With Large B-Cell Lymphoma Receiving Chimeric Antigen Receptor T-Cell Therapy. Journal of Clinical Oncology. 2024;42(2):205-217. doi:10.1200/jco.23.01097

BibTeX
@article{Iacoboni2024,
  author = {Iacoboni, Gloria and Navarro, Víctor and Martín-López, Ana África and Rejeski, Kai and Kwon, Mi and Jalowiec, Katarzyna Aleksandra and Amat, Paula and Reguera-Ortega, Juan Luis and Gallur, Laura and Blumenberg, Viktoria and Gutiérrez-Herrero, Sara and Roddie, Claire and Benzaquén, Ana and Delgado-Serrano, Javier and Sánchez-Salinas, Mario Andrés and Bailén, Rebeca and Carpio, Cecilia and López-Corral, Lucia and Hernani, Rafael and Bastos, Mariana and O'Reilly, Maeve and Martín-Martín, Lourdes and Subklewe, Marion and Barba, Pere},
  title = {Recent Bendamustine Treatment Before Apheresis Has a Negative Impact on Outcomes in Patients With Large B-Cell Lymphoma Receiving Chimeric Antigen Receptor T-Cell Therapy},
  journal = {Journal of Clinical Oncology},
  year = {2024},
  volume = {42},
  number = {2},
  pages = {205--217},
  doi = {10.1200/jco.23.01097}
}
Kostenlos starten →